J. Cosnes

Development of a New Index to Assess Small Bowel Inflammation Severity in Crohn’s Disease Using Magnetic Resonance Enterography
20221 citationsauthor #17
Large-scale sequencing identifies multiple genes and rare variants associated with Crohn’s disease susceptibility
2022130 citationsauthor #22
Sequencing of over 100,000 individuals identifies multiple genes and rare variants associated with Crohns disease susceptibility
20218 citationsauthor #22
Digestive-tract sarcoidosis : French nationwide case-control study of 25 cases
202110 citationsauthor #4
Increased incidence of systemic serious viral infections in patients with inflammatory bowel disease associates with active disease and use of thiopurines
202093 citationsauthor #8
Increased risk of permanent stoma in Crohn’s disease associated with hidradenitis suppurativa: a case‐control study
20205 citationsauthor #5
Nancy Index Scores of Chronic Inflammatory Bowel Disease Activity Associate With Development of Colorectal Neoplasia.
201929 citationsauthor #11
Genetic effects on the commensal microbiota in inflammatory bowel disease patients
201950 citationsauthor #9
Correction: Insights into the genetic epidemiology of Crohn's and rare diseases in the Ashkenazi Jewish population
20195 citationsauthor #27
Impact of vedolizumab therapy on extra‐intestinal manifestations in patients with inflammatory bowel disease: a multicentre cohort study nested in the OBSERV‐IBD cohort
2018109 citationsauthor #57
P199 Hidradenitis suppurativa associated with Crohn’s disease: An increased risk of permanent stoma
20180 citationsauthor #9
Specificities of the intestinal microbiota in patients with inflammatory bowel disease and Clostridium difficile infection
201892 citationsauthor #11
Risk of serious infection in healthcare workers with inflammatory bowel disease: a case‐control study of the Groupe d'Etude Thérapeutique des Affections Inflammatoires du tube Digestif (GETAID)
201814 citationsauthor #18
Features of Autoimmune Pancreatitis Associated With Inflammatory Bowel Diseases
201871 citationsauthor #35
Comparing Inpatient Satisfaction Collected via a Web-Based Questionnaire Self-Completion and Through a Telephone Interview: An Ancillary Study of the SENTIPAT Randomized Controlled Trial
20178 citationsauthor #3
One‐year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multicentre cohort study
2017155 citationsauthor #54
Chronic diarrhea
20170 citationsauthor #2
High Risk of Anal and Rectal Cancer in Patients With Anal and/or Perianal Crohn’s Disease
2017105 citationsauthor #12
Inflammatory Bowel Diseases: How to Identify High-Risk Patients
20170 citationsauthor #1
Autoimmune cytopenias associated with inflammatory bowel diseases: Insights from a multicenter retrospective cohort.
201734 citationsauthor #13
[Crohn's disease and hidradenitis suppurativa: An announced crisis?]
20170 citationsauthor #5
Chronic diarrhea: diagnostic strategy
20170 citationsauthor #2
Clostridium difficile infection in acute flares of inflammatory bowel disease: A prospective study.
201761 citationsauthor #9
Endoscopic Detection of Small Bowel Dysplasia and Adenocarcinoma in Crohn’s Disease: A Prospective Cohort-Study in High-Risk Patients
201729 citationsauthor #2
Long-term outcome of patients with steroid-refractory acute severe UC treated with ciclosporin or infliximab
2017137 citationsauthor #12
DOP011 Risk of opportunistic infection in healthcare personnel with inflammatory bowel disease: a case-control study of the GETAID.
20170 citationsauthor #18
Risk of Rectal Neoplasia after Colectomy and Ileorectal Anastomosis for Ulcerative Colitis
201743 citationsauthor #20
What Should Be Done in Inflammatory Bowel Disease Patients with Prior Malignancy?
201711 citationsauthor #1
Long-term Follow-up After Ileorectal Anastomosis for Ulcerative Colitis: A GETAID/GETAID Chirurgie Multicenter Retrospective Cohort of 343 Patients
201738 citationsauthor #2
Mo1852 Impact of Fertility Treatment on Inflammatory Bowel Disease Outcomes
20160 citationsauthor #8
Clinical Characteristics and Long-term Follow-up of 9 Cases
201673 citationsauthor #2
Excess risk of urinary tract cancers in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study
2016125 citationsauthor #7
Experts Opinion on the Practical Use of Azathioprine and 6-Mercaptopurine in Inflammatory Bowel Disease
201633 citationsauthor #4
Smoking and Diet: Impact on Disease Course?
201622 citationsauthor #1
Impact on Life Expectancy of Withdrawing Thiopurines in Patients with Crohn’s Disease in Sustained Clinical Remission: A Lifetime Risk-Benefit Analysis
201619 citationsauthor #5
Incidence and risk factors of serious viral infections in inflammatory bowel disease
20160 citationsauthor #8
Long-term Outcomes of Thalidomide Therapy for Adults With Refractory Crohn's Disease.
201628 citationsauthor #4
Recent advances in genome sequencing technologies are improving our understanding of the etiology of human
20160 citationsauthor #34
Insights into the genetic epidemiology of Crohn's and rare diseases in the Ashkenazi Jewish population
201681 citationsauthor #27
Fungal microbiota dysbiosis in IBD
20161,108 citationsauthor #11
1120 Incidence and Risk Factors of Serious Viral Infections in Inflammatory Bowel Disease
20160 citationsauthor #8
Negative Screening Does Not Rule Out the Risk of Tuberculosis in Patients with Inflammatory Bowel Disease Undergoing Anti-TNF Treatment: A Descriptive Study on the GETAID Cohort.
201665 citationsauthor #3
CARD9 impacts colitis by altering gut microbiota metabolism of tryptophan into aryl hydrocarbon receptor ligands
20161,237 citationsauthor #18
Sa1949 A Negative Screening Does Not Eliminate Tuberculosis Risk Under Anti-TNF Treatment in Inflammatory Bowel Disease: A Descriptive Study
20160 citationsauthor #3
Adalimumab or infliximab as monotherapy, or in combination with an immunomodulator, in the treatment of Crohn's disease
201647 citationsauthor #1
Azathioprine May Not be Associated With Development of Colorectal Tumors With Microsatellite Instability in Patients With Inflammatory Bowel Disease
20160 citationsauthor #10
Postoperative thiopurines in smokers with Crohn's disease.
20160 citationsauthor #1
Digestive-tract sarcoidosis
201623 citationsauthor #5
[Smoking, smoking cessation and Crohn's disease].
201611 citationsauthor #3
The outcome of infliximab dose doubling in 157 patients with ulcerative colitis after loss of response to infliximab
201522 citationsauthor #8
Benefit of infliximab reintroduction after successive failure of infliximab and adalimumab in Crohn's disease.
201520 citationsauthor #8
Development of the Lémann index to assess digestive tract damage in patients with Crohn's disease.
2015292 citationsauthor #31
829 Long-Term Outcomes in a Cohort of Patients With Acute Severe Ulcerative Colitis Refractory to Intravenous Steroids Treated With Cyclosporine or Infliximab
201514 citationsauthor #12
Factors Associated with Durable Response to Infliximab in Crohn's Disease 5 Years and Beyond: A Multicenter International Cohort
201536 citationsauthor #9
Sa1147 Course of Crohn's Disease (CD) in Thiopurine-Intolerant Patients
20150 citationsauthor #7
Mo1815 A Simple Biomarker for IBD Associated Dysbiosis:The Ratio of Iso-LCA/LCA Indicates Alteration of Isomeration of Bile Acids in the Intestinal Lumen
20151 citationsauthor #9
Changes in the Lémann Index Values During the First Years of Crohn's Disease.
201547 citationsauthor #10
Su1282 Endoscopic Detection of Small Bowel Adenocarcinoma and Dysplasia in Patients With Jejuno-Ileal Crohn's Disease: Prospective Study in a Cohort of High Risk Patients (DYDJI Study)
20150 citationsauthor #2
595 Ustekinumab Efficacy and Safety in Crohn's Disease Patients Refractory to Conventional and Anti-TNF Therapy: A Multicenter Retrospective Experience
20155 citationsauthor #5
Systemic adalimumab induces peripheral corneal infiltrates: a case report
201521 citationsauthor #4
Su1226 Evolution of the LéMann Index During the Course of Crohn's Disease
20150 citationsauthor #9
Sa1118 Withdrawing or Continuing Maintenance Treatment With Thiopurines in Patients With Crohn's Disease in Sustained Clinical Remission: A Lifetime Risk-Benefit Analysis
20152 citationsauthor #3
P247 Development of a new tool to assess Crohn's disease magnetic resonance inflammation severity
20140 citationsauthor #6
Reply: To PMID 23644079.
20140 citationsauthor #1
Prevalence and risk factors of Clostridium difficile infection in patients hospitalized for flare of inflammatory bowel disease: a retrospective assessment.
201455 citationsauthor #8
Complications and surgery in the inflammatory bowel diseases biological era
201446 citationsauthor #3
Milder multiple sclerosis course in patients with concomitant inflammatory bowel disease
201430 citationsauthor #13
Su1392 Benefit of Infliximab Re-Introduction After Successive Failure of Infliximab and Adalimumab in Crohn's Disease
20140 citationsauthor #8
Cap polyposis and colitis cystica profunda: a rare association
201411 citationsauthor #5
Long-Term Outcome of Enterocutaneous Fistula in Patients With Crohn's Disease Treated With Anti-TNF Therapy: A Cohort Study from the GETAID
201477 citationsauthor #14
Rectocolite hémorragique : du diagnostic au traitement
20140 citationsauthor #4
The impact of cytomegalovirus reactivation and its treatment on the course of inflammatory bowel disease
201471 citationsauthor #6
Impact of the diagnosis and treatment of cancer on the course of inflammatory bowel disease.
201430 citationsauthor #7
Small Bowel Adenocarcinomas Complicating Crohn's Disease Are Associated With Dysplasia: A Pathological and Molecular Study
201472 citationsauthor #3
P482 Impact of cytomegalovirus reactivation treatment on inflammatory bowel disease flare
20130 citationsauthor #6
Overexpression of microRNAs-155 and 21 targeting mismatch repair proteins in inflammatory bowel diseases.
201355 citationsauthor #6
6 Development of the Crohn's disease (CD) digestive damage score: the Lémann score
20135 citationsauthor #4
950 Factors Associated With Durable Response to Infliximab 5 Years and Beyond: A Multi Center International Cohort
20131 citationsauthor #9
Portomesenteric Vein Thrombosis in Patients With Inflammatory Bowel Disease
201341 citationsauthor #3
P516 Efficacy of adalimumab in refractory ulcerative colitis in clinical practice
20132 citationsauthor #9
[Complications of celiac disease].
20130 citationsauthor #1
Perceived personal controllability of IBD patients and the method of administering treatment
20130 citationsauthor #3
P692 Quorum sensing driven by N-acyl-homoserine lactone in inflammatory bowel diseases associated dysbiosis
20130 citationsauthor #6
P638 Impact of extra-intestinal cancer diagnosis and treament on inflammatory bowel disease outcome
20133 citationsauthor #7
Sa1804 Quorum Sensing Driven by N-Acyl-Homoserine Lactone in Inflammatory Bowel Diseases Associated Dysbiosis
20136 citationsauthor #6
Is there still a room for azathioprine monotherapy in inflammatory bowel disease?
20134 citationsauthor #3
555 What Is the Prognosis of Silent Crohn's Disease ?
20137 citationsauthor #7
Long-term outcome of patients with Crohn's disease who respond to azathioprine.
201367 citationsauthor #8
Tu1105 Development of the Crohn's Disease (CD) Digestive Damage Score: The LéMann Score
20131 citationsauthor #4
Early administration of azathioprine vs conventional management of Crohn's Disease: a randomized controlled trial.
2013277 citationsauthor #1
Sa1104 Efficacy of Adalimumab in Refractory Ulcerative Colitis in Clinical Practice
20131 citationsauthor #9
P116 What is the prognosis of silent Crohn's disease?
20131 citationsauthor #7
Measuring structural damage in Crohn's disease.
20133 citationsauthor #1
Early azathioprine in Crohn's disease.
20134 citationsauthor #1
Mo1267 Impact of Cytomegalovirus Reactivation Treatment on Inflammatory Bowel Disease Flare
20130 citationsauthor #6
Connecting dysbiosis, bile-acid dysmetabolism and gut inflammation in inflammatory bowel diseases
2012803 citationsauthor #16
Factors affecting outcomes in Crohn's disease over 15 years
2012128 citationsauthor #1
Mo1699 Recent Treatment With Nonsteroidal Anti-Inflammatory Drugs is an Independent Risk Factor for Clostridium difficile Infection in Patients Hospitalized for Active Inflammatory Bowel Disease
20120 citationsauthor #8
943c ACCELERATED STEP-CARE THERAPY WITH EARLY AZATHIOPRINE (AZA) VS. CONVENTIONAL STEP-CARE THERAPY IN CROHN'S DISEASE. A RANDOMIZED STUDY.
201216 citationsauthor #1
How to Identify High-Risk Patients in Inflammatory Bowel Disease?
20124 citationsauthor #1

PROFILE

PAPERS

TIMELINE

COAUTHOR MAP

CONCEPT FOOTPRINT